Executive transition and upcoming earnings put Avient in focus

Avient (AVNT) has drawn attention as investors weigh an upcoming earnings report alongside an announced finance leadership change, with long-serving executive Giuseppe Di Salvo set to become Chief Financial Officer on June 1, 2026.

The upcoming earnings report and CFO transition come as Avient’s share price sits at US$36.76 after a 1 month share price return of 4.82% and a year to date share price return of 15.93%. However, the 5 year total shareholder return of a 22.52% loss highlights how longer term holders have faced a tougher journey.

If you are weighing Avient’s setup around earnings and leadership changes, it can be useful to compare it with other opportunities using our 17 top founder-led companies

With Avient trading at US$36.76 and screens suggesting around a 30% intrinsic discount alongside a sizeable gap to analyst targets, you have to ask: is there real mispricing here, or is the market already baking in future growth?

Most Popular Narrative: 24.3% Undervalued

With Avient last closing at $36.76 against a narrative fair value of $48.57, the prevailing view is that the current price leaves meaningful room to close that gap.

Ongoing footprint optimization, Lean Six Sigma initiatives, and discretionary spending controls are structurally lowering operating costs and improving productivity, leading to sustained improvements in EBITDA margins and higher free cash flow generation.

Want to see what sits behind that margin story? The narrative leans on steadier revenue, expanding profitability and a different earnings multiple than today. The full framework is all about the numbers.

Result: Fair Value of $48.57 (UNDERVALUED)

However, this setup still hinges on healthy demand in key end markets and manageable raw material costs, both of which could quickly challenge that undervaluation story.

Another angle from earnings multiples

That 24.3% narrative undervaluation sits alongside a much less generous signal from P/E. Avient trades on a P/E of 41.2x, compared with 30x for the US Chemicals industry, 25.3x for peers and a fair ratio estimate of 27x, which points to valuation risk if expectations slip.

To see how that richer earnings multiple fits with the rest of the numbers, take a closer look at the valuation breakdown using the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of risks and rewards around Avient is clear, so move quickly, review the data for yourself, and weigh the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

Do not stop with a single stock when you can quickly scan other opportunities that match your style, risk comfort and income goals.

• Target quality at a discount by checking companies that appear mispriced on strong fundamentals using the 51 high quality undervalued stocks.
• Secure potential income streams by reviewing companies that screen for robust payouts and higher yields through the 13 dividend fortresses.
• Prioritise resilience by focusing on companies with sturdier finances and fewer red flags using the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.